MAVENIR
Vodafone Portugal, a leading telecom provider in Portugal, and Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced that Vodafone Portugal will be using the MAVcore solution for its fully containerised Converged Packet Core network after the selection of Mavenir as strategic 5G Converged Core supplier.
The MAVcore family includes Mavenir’s leading-edge Converged Packet Core and Policy Control solution delivering a next-generation modernised data network. The MAVcore solution will allow the transformation to a containerised and automated cloud-native network – providing the flexibility for future mobile network evolution, including the launch of disruptive and innovative 5G Stand Alone applications for Vodafone customers in Portugal.
The 5G Converged Packet Core solution is designed with cloud-native containerised techniques providing a fully scalable and virtualised network architecture. The solution uses software running on commercial off-the-shelf (COTS) hardware that provides cost-effectiveness, flexibility, and agility. Mavenir Converged Packet Core with multi-access support (2G, 3G, 4G, 5G) allows Communication Service Providers (CSPs) like Vodafone to plan for future growth and a greater focus on security and reliability. It simplifies network transformation and enables operational efficiencies with complete automation.
Paulino Correa, Network Director, Vodafone Portugal, said; “The industry defines several steps for 5G – the first one was launched back in November – but it is the second step, the 5G Stand Alone Core, that brings the more powerful technology revolution in terms of use cases. For our strategic 5G Stand Alone Core supplier, we wanted a vendor who would have innovation at its heart and equally provide us with a technically leading converged Packet Core solution. We have been working on 5G SA with Mavenir in our lab for over 1 year and are now ready to deliver a cloud-native Packet Core platform that will transform our network and prepare it for powerful applications and differentiating use cases, as the 5G solution evolves.”
Stefano Cantarelli, Chief Marketing Officer, Mavenir, said; “Mavenir has been working with Vodafone Group across various projects and we are delighted to now be part of their next-generation Converged Packet Core network under the Spring 3 Cosmos programme – we look forward to transforming Vodafone Portugal’s existing network into a dynamic, agile, fully automated for simplified operation and cloud-native based platform.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Vodafone Portugal:
Vodafone Portugal is part of the Vodafone Group which is a leading technology communications company. Vodafone is the largest mobile and fixed network operator in Europe and a leading global IoT connectivity provider. Vodafone Group operates mobile and fixed networks in 21 countries and partner with mobile networks in 48 more. Vodafone Portugal currently serves 3.6 million homes and businesses with its next generation network and has over 4.6 million mobile customers.
https://www.vodafone.pt/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom